Medine.co.uk

Multimin Solution For Injection For Cattle

Issued: July 2015

AN: 00451/2013

SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


Multimin Solution for Injection for Cattle


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


Each ml contains


Active substances:

Zinc: 60 mg,

(equivalent to zinc oxide: 74.68 mg)

Manganese: 10 mg,

(equivalent to manganese carbonate: 22.73 mg)

Copper: 15 mg,

(equivalent to copper sulphate pentahydrate: 58.92 mg)

Selenium: 5 mg,

(equivalent to sodium selenite: 11.11 mg)


Excipients:

Benzyl alcohol 10.4mg


For the full list of excipients, see section 6.1.


3. PHARMACEUTICAL FORM

Solution for injection

Clear blue solution


4. CLINICAL PARTICULARS


4.1 Target species


Cattle.


4.2 Indications for use, specifying the target species


Supply of trace minerals to correct concurrent clinical or subclinical deficiencies of selenium, copper, manganese and zinc which can arise during critical phases of the production or breeding life cycle.


4.3 Contraindications


None.



4.4 Special warnings for each target species


None.


4.5 Special precautions for use


Special precautions for use in animals


Additional copper, zinc, manganese or selenium should not be administered at the same time.

Use standard aseptic procedures during administration of injections.

Strict adherence to correct subcutaneous injection technique should be employed.

Ensure that animals are properly restrained, including those in the vicinity.

Special precautions to be taken by the person administering the veterinary medicinal product to animals


This product can cause skin and eye irritation. Avoid contact with skin or eyes.

If accidental skin exposure occurs, wash skin immediately with soap and water.

If product accidentally gets into eyes, rinse immediately with clean water.


This product is HIGHLY concentrated in Selenium.


Due to a potential risk of Selenium toxicity, care should be taken when handling the product to avoid accidental self-injection.


When treating a large number of animals, a safe injection system should be used.


Do not work alone when using the product.


In the event of accidental self-injection, SEEK IMMEDIATE MEDICAL ATTENTION and take the vial or package leaflet with you.


Wash hands after use.


4.6 Adverse reactions (frequency and seriousness)


Pain is very commonly observed during injection and within the first few hours after injection. Local reactions at the injection site are very common and consist of transient mild to moderate swelling that evolves into induration estimated at less than 1cm at palpation after 14 days.


The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)

- common (more than 1 but less than 10 animals in 100 animals)

- uncommon (more than 1 but less than 10 animals in 1,000 animals)

- rare (more than 1 but less than 10 animals in 10,000 animals)

- very rare (less than 1 animal in 10,000 animals, including isolated reports


4.7 Use during pregnancy, lactation or lay


Pregnancy:

Can be used during pregnancy.


Lactation:

Can be used during lactation.

4.8 Interaction with other medicinal products and other forms of interaction


None known.


4.9 Amounts to be administered and administration route

Strictly Subcutaneous route.


Dose:

Cattle - Up to 1 year: 1ml per 50kg


Schedule of administration:


To be administered as a single administration during, or in advance of, periods of stress in the production and breeding life cyclelikely to result in concurrent clinical or subclinical deficiencies of the four trace minerals(for example, transport/shipping, calving, breeding).


Maximal volume per injection site: 7ml


4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary


Repeated overdosing (3 consecutive administrations) at one to three times the recommended dose (i.e. 3x – 9x recommended dose) is well tolerated systemically in cattle.


Repeated overdosing (3 consecutive administrations) at five times the recommended dose (i.e. 15x recommended dose) is associated with elevation of liver enzymes and centrilobular hepatocellular degeneration limited to two animals out of eight.


4.11 Withdrawal period(s)

Meat and offal: 8 days.

Milk: zero hours.


5. PHARMACOLOGICAL PROPERTIES


Pharmacotherapeutic group: mineral supplements.

ATCvet code: QA12CX99.



5.1 Pharmacodynamic properties


Manganese is indispensable for the action of glycotransferase. This enzyme plays a role in the formation of the mucopolysaccharide chondroitin sulphate, which is a component of cartilage and due to its action on the formation of cartilage, it is also important for bone formation. Mn is an important component of Mn superoxide dismuatase enzyme used in the enzymatic antioxidant system.

Although manganese is also part of pyruvic carboxylase and several other enzymes, other divalent cations may serve as alternatives for its role in the activity of these enzymes.


Copper forms an integral part of a number of metalloproteins notably caeruloplasmin, monoamine oxidase, lysyl oxidase, cytochrome C and superoxide dismutase enzymes.

Zinc acts as a cofactor of numerous enzymes, e.g. alcohol dehydrogenase, carbonic anhydrase and carboxypeptidase. Zn is an important component of Zn superoxide dismutase enzyme used in the enzymatic antioxidant system. Zinc plays a role in protein synthesis and cell division. It also exerts crucial influence on the maintenance of cell membrane stability and in the function of the immune system. The connection between the known physiological functions of zinc and the various manifestations of zinc deficiency remain largely unexplained. Zinc interacts with several metabolic ions. Copper, calcium and phytate (a constituent of cereals) reduce zinc absorption; cadmium and zinc compete with each other.


Selenium exerts an antioxidative effect at the cell membrane against hydrogen peroxide and lipoperoxides. The effects are related to enzymatic activity of glutathione peroxidase (GSHPx) which contains selenocysteine. Selenium’s protective antioxidative action is partially linked to that of vitamin E. Selenocysteine is also an integral component of other functional proteins e.g. tetra- idothyronine-5-I-deiodinase (involved in metabolism of thyroid hormones) but the full extent of the biochemical mode of action of selenium in the body still remains to be elucidated.


5.2 Pharmacokinetic particulars


Absorption:

Following subcutaneous administration, the trace minerals are rapidly absorbed from the injection site.


Distribution:


Metabolism:

The metabolic process involving selenium is dependent on the chemical form and dose as well as on nutritional status. Major metabolites are methylated selenites. Two major metabolic products of selenite have been identified: dimethyl selenide and a tri­­methyl­­selenonium ion.


Excretion:


6. PHARMACEUTICAL PARTICULARS


6.1 List of excipients


Benzyl alcohol (E1519)

Edetic acid

Sodium hydroxide

Water for injections


6.2 Incompatibilities


In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.


6.3 Shelf life


Shelf life of the veterinary medicinal product as packaged for sale: 2 years

Shelf life after first opening the immediate packaging: 28 days


6.4. Special precautions for storage


This veterinary medicinal product does not require any special storage conditions.


6.5 Nature and composition of immediate packaging


1 x 100 ml clear Polyethylene Terephthalate bottle closed with grey bromobutyl rubber stopper sealed with aluminium cap.

1 x 500ml clear Polyethylene Terephthalate bottle closed with grey bromobutyl rubber stopper sealed with aluminium cap.


Not all sizes may be marketed.


6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.


7. MARKETING AUTHORISATION HOLDER


Warburton Technology Limited

36 Fitzwilliam Square

Dublin 2

IRELAND


8. MARKETING AUTHORISATION NUMBER


Vm 42511/4000


9. DATE OF FIRST AUTHORISATION


14 July 2015


10. DATE OF REVISION OF THE TEXT


July 2015


APPROVED 14/07/15

Page 6 of 6